Semarion

Semarion introduces SemaCyte Multiplexing Platform to enhance cell assay data quality and speed during drug discovery

Expansion to SemaCyte Microcarrier platform enables optical barcoding and pooling of adherent cells to augment drug discovery high-content imaging and other screening processes Access available through Semarion’s Early Adopter Programme. 20 March 2024 -- Cambridge, UK -- Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to...

Semarion announces Early Adopter Programme for SemaCyte Microcarrier Platform

SemaCyte Microcarrier Platform addresses limitations within adherent cell assays to accelerate the pace of in vitro drug discovery Early access will further validate the technology and provide feedback on applicability across customer workflows 18 October 2023 -- Cambridge, UK -- Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering...
Cavendish Laboratories JJ Thomson Ave Cambridge CB3 0HE UK